Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 8, 2026, 10:13 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–3 of 3 matching trials from the live ClinicalTrials.gov search.
Conditions
Parkinson Disease
Interventions
Placebo, PF-06649751 low dose (1 mg QD), PF-06649751 middle dose 1 (3 mg QD), PF-06649751 middle dose 2 (7 mg QD), PF-06649751 high dose (15 mg QD)
Drug
Lead sponsor
Pfizer
Industry
Eligibility
40 Years to 85 Years
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
33
States / cities
Phoenix, Arizona • Arcadia, California • Loma Linda, California + 26 more
Conditions
Parkinson Disease
Interventions
Tavapadon
Drug
Lead sponsor
Cerevel Therapeutics, LLC
Industry
Eligibility
45 Years to 80 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
6
States / cities
Los Alamitos, California • Hollywood, Florida • Orlando, Florida + 3 more
Conditions
Parkinson's Disease With Motor Fluctuations
Interventions
1 mg QD to 15 mg QD PF-06649751, 3 mg QD to 15 mg QD PF-06649751, 7 mg QD to 15 mg QD PF-06649751, 15 mg QD PF-06649751, 1 mg QD to 7 mg QD PF-06649751 (if de-escalated in parent study), 3 mg QD to 7 mg QD PF-06649751 (de-escalated in parent study), 7 mg QD to 7 mg QD PF-06649751 (de-escalated in parent study), 15 mg QD de-escalated to 7 mg QD PF-06649751 in parent study remain at 7 mg QD
Drug
Lead sponsor
Pfizer
Industry
Eligibility
40 Years to 87 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
9
States / cities
Newport Beach, California • Fairfield, Connecticut • Boca Raton, Florida + 5 more